Takeda benefits from one-offs but Actos already weighing heavily
This article was originally published in Scrip
The main take-aways from Takeda's first quarter figures were the precipitous plunges in both group operating profit and global sales of top product Actos (pioglitazone) ahead of the oral antidiabetic's loss of US exclusivity next month.
You may also be interested in...
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.